



**A R A D**  
Australian Rheumatology Association Database

**6 monthly report (April 2010) – Australian Rheumatology Association Database (ARAD).**

**A study of the long-term effects of arthritis and its treatments in Australia**

This report provides a summary of the data collected from participants enrolled in ARAD up to April 2010.

To 1<sup>st</sup> April 2010, 3025 patients across Australia have enrolled in ARAD and 222 rheumatologists are participating.

The mean HAQ and AQL scores for all ARAD patients taking biologics are shown in Table 1.

The number of patient-reported severe infections in patients on biologics is reported in Table 2.

The number of patient-reported TB infections since 2006 is shown in Table 3.

The frequency of patient-reported reasons for discontinuation of biologics is outlined in Table 4.

**Funding Acknowledgements**

- NHMRC Enabling Grant
- Monash University
- Educational grants to the ARA from Abbott Australasia Pty Ltd, Roche Products Pty Ltd, Wyeth Australia Pty Ltd.

**Table 1 HAQ and AqoL scores for all ARAD patients receiving biological therapy from commencement of bDMARDs**

	<b>HAQ score</b> (0-3, 0 = no disability)	<b>AqoL score</b> (0.00 = death; 1.00 = full health)
	<i>Patients receiving biologics (n = 2815)</i>	<i>Patients receiving biologics (n = 2815)</i>
Age in most recent questionnaire mean (SD)	54.64 (14.60) years	
Proportion of females (%)	64.58%	
Timepoint since starting biologics	Mean (SD)	Mean (SD)
<b>Baseline - 6 months</b>	1.219 (0.728) n = 1,894	0.499 (0.241) n = 1,885
<b>6-12 Months</b>	1.061 (0.750) n = 1,664	0.552 (0.243) n = 1,651
<b>12-18 Months</b>	1.016 (0.752) n = 1,500	0.561 (0.243) n = 1,494
<b>18-24 Months</b>	1.008 (0.751) n = 1,359	0.561 (0.240) n = 1,351
<b>24-30 Months</b>	1.048 (0.769) n = 1,314	0.553 (0.242) n = 1,306
<b>30-36 Months</b>	1.044 (0.778) n = 1,149	0.544 (0.253) n = 1,143
<b>36-42 Months</b>	1.104 (0.785) n = 981	0.537 (0.252) n = 973
<b>42-48 Months</b>	1.143 (0.797) n = 798	0.528 (0.254) n = 797
<b>48-54 Months</b>	1.141 (0.787) n = 619	0.536 (0.253) n = 619
<b>54-60 Months</b>	1.190 (0.816) n = 480	0.530 (0.253) n = 480
<b>60-66 Months</b>	1.213 (0.816) n = 359	0.528 (0.256) n = 357
<b>66-72 Months</b>	1.296 (0.800) n = 262	0.489 (0.264) n = 262
<b>72-78 Months</b>	1.271 (0.784) n = 162	0.496 (0.262) n = 162
<b>78-84 Months</b>	1.101 (0.769) n = 85	0.496 (0.257) n = 85
<b>84-90 Months</b>	1.088 (0.818) n = 62	0.520 (0.278) n = 61
<b>90-96 Months</b>	1.194 (0.768) n = 40	0.506 (0.221) n = 40
<b>96-102 Months</b>	1.261 (0.770) n = 23	0.523 (0.243) n = 23
<b>102-108 Months</b>	1.234 (0.723) n = 11	0.547 (0.249) n = 10
<b>108-114 Months</b>	1.438 (0.899) n = 8	0.543 (0.297) n = 8
<b>114-120 Months</b>	1.833 (0.938) n = 3	0.389 (0.316) n = 3
<b>120-126 Months</b>	1.813 (1.326) n = 2	0.527 (0.515) n = 2
<b>126-132 Months</b>	1.708 (0.753) n = 3	0.392 (0.377) n = 3

Patients with a diagnosis of AS or JIA (<= 16 yrs old) have a HAQ-S or HAQ-C score respectively calculated. HAQ scores: 0 -3, 0= no disability, 3 = worst function, being unable to perform most daily activities; AqoL scores: negative scores indicate a state worse than death; 0.00 is death; 1.00 is full health; NB improvements in HAQ and AqoL are in different direction

**Table 2** Number of severe infections reported between January 2006 and March 2010

Type of infection	Time period post bDMARD													
	Baseline - 6 Months	6-12 Months	12-18 Months	18-24 Months	24-30 Months	30-36 Months	36-42 Months	42-48 Months	48-54 Months	54-60 Months	60-66 Months	66-72 Months	72-78 Months	78-84 Months
Skin or nail	25	21	26	22	18	18	14	17	9	11	5	4	6	4
Eye, ear, nose or throat	27	29	38	32	30	22	20	12	13	10	5	7	1	4
Heart	-	-	4	3	2	1	1	-	2	-	-	-	2	2
Chest or lung	30	37	33	35	40	26	22	20	20	15	14	11	5	2
Stomach, gut, gall bladder or liver	19	18	9	14	14	8	8	11	3	5	-	3	-	1
Kidney, bladder or urine	17	14	15	11	21	16	13	14	4	5	1	3	1	1
Bone, joint or muscle	22	21	18	18	17	26	15	19	8	2	2	9	3	-
Artificial joint or muscle	1	2	9	2	3	9	2	4	1	2	5	2	-	1
Brain or spinal cord	1	2	-	2	1	-	2	-	-	1	1	-	-	-
Blood	3	5	6	5	13	8	8	5	1	1	4	1	1	-
Viral	19	16	21	17	16	12	16	8	7	11	2	5	3	3
Other	8	9	13	16	10	9	6	6	5	3	-	2	1	-
<b>Total severe infections</b>	172	174	192	177	185	155	127	116	73	66	39	47	23	18
Number of persons with at least one severe infection	127	130	141	128	135	115	97	93	56	48	28	34	22	10
<b>Total n at time point</b>	1,170	1,230	1,267	1,230	1,238	1,115	947	780	608	476	358	259	162	84

**Table 3** Patient-Reported TB infections since 2006\*

Severity of Infection	Time period post bDMARD						Total
	Baseline - 6 months	6-12 Months	12-18 Months	18-24 Months	24-30 Months	54-60 Months	
Mild	-	3	1	1	-	1	6
Moderate	2	1	1	-	2	-	6
<b>Total</b>	2	4	2	1	2	1	12

\* All TB reports are currently being validated

**Table 4 Summary of reasons for discontinuation of biological therapy**

Reason	Enbrel Etanercept N=659	Remicade Infliximab N=241	Humira Adalimumab N=566	Kineret Anakinra N=38	MabThera Rituximab N=62	Orencia Abatacept N=24	Actemra Tocilizumab N=2
<b>Number stopping</b>							
<b>Lack of efficacy</b>	257	92	239	13	31	11	1
<b>Side effect</b>	156	49	127	5	7	4	-
<b>Allergic reaction</b>	22	13	18	1	1	-	-
<b>General</b>	32	13	28	1	-	1	-
<b>Skin</b>	43	10	41	2	5	2	-
<b>Eye/Ear/Nose/Throat</b>	18	2	4	-	-	-	-
<b>Stomach/Bowel/Liver</b>	18	4	9	-	2	1	-
<b>Lungs</b>	14	5	9	-	2	-	-
<b>Cardiovascular</b>	13	10	8	-	-	-	-
<b>Neurological &amp; psychological</b>	10	4	10	-	-	1	-
<b>Infections</b>	32	3	22	-	-	1	-
<b>Abnormal tests</b>	22	5	13	1	-	1	-
<b>Musculoskeletal</b>	1	-	-	-	-	-	-
<b>Other</b>	-	1	-	-	-	-	-
<b>Total side effects reported</b>	225	71	162	5	10	7	-
<b>Not specified</b>	8	4	15	2	-	-	-
<b>Arthritis improved</b>	10	3	9	-	10	1	-
<b>Too sick from other illness</b>	29	7	28	2	1	2	-
<b>Failed PBS criteria</b>	27	10	20	1	2	1	-
<b>Preparing for surgery</b>	14	1	16	-	-	2	1
<b>Planning pregnancy</b>	13	4	10	-	2	-	-
<b>Clinical trial finished</b>	-	8	-	11	1	-	-
<b>Did not like it /worried about the ....</b>	8	2	4	-	-	-	-
<b>Other</b>	2	-	-	-	1	-	-
<b>Started new drug</b>	131	61	101	4	5	3	-
<b>Did not like delivery method</b>	3	1	5	-	-	-	-
<b>Not specified</b>	9	3	6	2	2	-	-

Data in this table represent the frequency of nominal responses selected by patients for therapy discontinuation for each bDMARD.